Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines
Despite the existence of a highly efficient yellow fever vaccine, yellow fever reemergence throughout Africa and the Americas has put 900 million people in 47 countries at risk of contracting the disease. Although the vaccine has been key to controlling yellow fever epidemics, its live-attenuated na...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1895644 |
| _version_ | 1827807673233440768 |
|---|---|
| author | Gerardo Montalvo Zurbia-Flores Christine S Rollier Arturo Reyes-Sandoval |
| author_facet | Gerardo Montalvo Zurbia-Flores Christine S Rollier Arturo Reyes-Sandoval |
| author_sort | Gerardo Montalvo Zurbia-Flores |
| collection | DOAJ |
| description | Despite the existence of a highly efficient yellow fever vaccine, yellow fever reemergence throughout Africa and the Americas has put 900 million people in 47 countries at risk of contracting the disease. Although the vaccine has been key to controlling yellow fever epidemics, its live-attenuated nature comes with a range of contraindications that prompts advising against its administration to pregnant and lactating women, immunocompromised individuals, and those with hypersensitivity to chicken egg proteins. Additionally, large outbreaks have highlighted problems with insufficient vaccine supply, whereby manufacturers rely on slow traditional manufacturing processes that prevent them from ramping up production. These limitations have contributed to an inadequate control of yellow fever and have favored the pursuit of novel yellow fever vaccine candidates that aim to circumvent the licensed vaccine’s restrictions. Here, we review the live-attenuated vaccine’s limitations and explore the epitome of a yellow fever vaccine, whilst scrutinizing next-generation vaccine candidates. |
| first_indexed | 2024-03-11T22:00:43Z |
| format | Article |
| id | doaj.art-7ed3c8f4b99442c59b253fabf4a578d0 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:00:43Z |
| publishDate | 2022-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-7ed3c8f4b99442c59b253fabf4a578d02023-09-25T11:17:06ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-01-0118110.1080/21645515.2021.18956441895644Re-thinking yellow fever vaccines: fighting old foes with new generation vaccinesGerardo Montalvo Zurbia-Flores0Christine S Rollier1Arturo Reyes-Sandoval2University of Oxford. The Henry Wellcome Building for Molecular PhysiologyUniversity of Oxford and the NIHR Oxford Biomedical Research CentreUniversity of Oxford. The Henry Wellcome Building for Molecular PhysiologyDespite the existence of a highly efficient yellow fever vaccine, yellow fever reemergence throughout Africa and the Americas has put 900 million people in 47 countries at risk of contracting the disease. Although the vaccine has been key to controlling yellow fever epidemics, its live-attenuated nature comes with a range of contraindications that prompts advising against its administration to pregnant and lactating women, immunocompromised individuals, and those with hypersensitivity to chicken egg proteins. Additionally, large outbreaks have highlighted problems with insufficient vaccine supply, whereby manufacturers rely on slow traditional manufacturing processes that prevent them from ramping up production. These limitations have contributed to an inadequate control of yellow fever and have favored the pursuit of novel yellow fever vaccine candidates that aim to circumvent the licensed vaccine’s restrictions. Here, we review the live-attenuated vaccine’s limitations and explore the epitome of a yellow fever vaccine, whilst scrutinizing next-generation vaccine candidates.http://dx.doi.org/10.1080/21645515.2021.1895644yellow feveryellow fever vaccinelive-attenuated vaccinevaccine shortagevaccine contraindicationsyellow fever next-generation vaccinesdisease controlglobal healthemerging disease |
| spellingShingle | Gerardo Montalvo Zurbia-Flores Christine S Rollier Arturo Reyes-Sandoval Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines Human Vaccines & Immunotherapeutics yellow fever yellow fever vaccine live-attenuated vaccine vaccine shortage vaccine contraindications yellow fever next-generation vaccines disease control global health emerging disease |
| title | Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines |
| title_full | Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines |
| title_fullStr | Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines |
| title_full_unstemmed | Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines |
| title_short | Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines |
| title_sort | re thinking yellow fever vaccines fighting old foes with new generation vaccines |
| topic | yellow fever yellow fever vaccine live-attenuated vaccine vaccine shortage vaccine contraindications yellow fever next-generation vaccines disease control global health emerging disease |
| url | http://dx.doi.org/10.1080/21645515.2021.1895644 |
| work_keys_str_mv | AT gerardomontalvozurbiaflores rethinkingyellowfevervaccinesfightingoldfoeswithnewgenerationvaccines AT christinesrollier rethinkingyellowfevervaccinesfightingoldfoeswithnewgenerationvaccines AT arturoreyessandoval rethinkingyellowfevervaccinesfightingoldfoeswithnewgenerationvaccines |